BIO vs. WAT, ILMN, BIO.B, RVTY, TXG, OLK, AVTR, EHC, PEN, and ASND
Should you be buying Bio-Rad Laboratories stock or one of its competitors? The main competitors of Bio-Rad Laboratories include Waters (WAT), Illumina (ILMN), Bio-Rad Laboratories (BIO.B), Revvity (RVTY), 10x Genomics (TXG), Olink Holding AB (publ) (OLK), Avantor (AVTR), Encompass Health (EHC), Penumbra (PEN), and Ascendis Pharma A/S (ASND). These companies are all part of the "medical" sector.
Waters (NYSE:WAT) and Bio-Rad Laboratories (NYSE:BIO) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, media sentiment, community ranking, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.
Waters presently has a consensus price target of $298.67, indicating a potential downside of 5.21%. Bio-Rad Laboratories has a consensus price target of $468.00, indicating a potential upside of 68.89%. Given Waters' stronger consensus rating and higher possible upside, analysts clearly believe Bio-Rad Laboratories is more favorable than Waters.
Waters has a beta of 0.92, indicating that its share price is 8% less volatile than the S&P 500. Comparatively, Bio-Rad Laboratories has a beta of 0.87, indicating that its share price is 13% less volatile than the S&P 500.
Waters received 68 more outperform votes than Bio-Rad Laboratories when rated by MarketBeat users. However, 64.93% of users gave Bio-Rad Laboratories an outperform vote while only 54.58% of users gave Waters an outperform vote.
Waters has higher revenue and earnings than Bio-Rad Laboratories. Bio-Rad Laboratories is trading at a lower price-to-earnings ratio than Waters, indicating that it is currently the more affordable of the two stocks.
Waters has a net margin of 21.72% compared to Waters' net margin of -23.86%. Bio-Rad Laboratories' return on equity of 81.30% beat Waters' return on equity.
94.0% of Waters shares are owned by institutional investors. Comparatively, 65.2% of Bio-Rad Laboratories shares are owned by institutional investors. 0.8% of Waters shares are owned by company insiders. Comparatively, 17.5% of Bio-Rad Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
In the previous week, Waters had 31 more articles in the media than Bio-Rad Laboratories. MarketBeat recorded 39 mentions for Waters and 8 mentions for Bio-Rad Laboratories. Waters' average media sentiment score of 0.78 beat Bio-Rad Laboratories' score of 0.26 indicating that Bio-Rad Laboratories is being referred to more favorably in the news media.
Summary
Waters beats Bio-Rad Laboratories on 12 of the 18 factors compared between the two stocks.
Get Bio-Rad Laboratories News Delivered to You Automatically
Sign up to receive the latest news and ratings for BIO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Bio-Rad Laboratories Competitors List
Related Companies and Tools
